Entrada Therapeutics, Inc. TRDA
6.16
(0.06)
(0.96%)
as of 25 Sep
- Market cap
- $242.2M
- P/E
- 0.0×
Follow TRDA
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.91 | 16.73 | 92.01 | 66.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(8.49) | (13.21) | (12.66) | (9.57) | |
P/B ratio |
0.71 | 1.39 | 1.95 | 1.33 | |
Price to Tangible BV |
0.71 | 1.39 | 1.95 | 1.33 | |
EV/Sales |
(1.40) | 5.07 | 47.60 | 18.73 | |
EV/EBITDA |
0.70 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.68 | (1.00) | (2.07) | (0.65) | |
EV/FCF |
0.67 | (1.00) | (2.07) | (0.65) | |
Quick Ratio |
13.66 | 12.17 | 13.32 | 10.47 | |
Current Ratio |
14.08 | 12.53 | 13.90 | 10.89 | |
Net Debt/EBITDA |
7.02 | 7.06 | 6.06 | 5.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.13 | 0.06 | 0.01 | 0.01 | |
Operating CF/Net income |
0.64 | 0.82 | 1.05 | 0.76 | |
Capex/Depreciation |
0.35 | 0.82 | (0.17) | (0.03) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,376.77% | 2,614.09% | 3,777.60% | 3,938.64% | |
Selling, General and Administrative Expense of Revenue |
638.41% | 735.18% | 1,157.03% | 1,168.37% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
316.98% | 335.49% | 542.17% | 573.50% | |
Graham Net Nets |
1.11 | 0.55 | 0.38 | 0.54 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(42.93%) | (33.66%) | (31.62%) | (53.80%) | |
Free Cash Flow Yield |
(53.97%) | (30.46%) | (24.93%) | (43.23%) | |
Revenue per Share |
0.04 | 0.03 | 0.02 | 0.02 | |
Operating CF per Share |
(0.68) | (0.78) | (1.00) | (0.77) | |
Capex per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.68) | (0.77) | (1.00) | (0.77) | |
Cash per Share |
7.88 | 7.16 | 6.09 | 5.28 | |
Shareholders Equity per Share |
8.22 | 7.40 | 6.47 | 5.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.22 | 7.40 | 6.47 | 5.53 | |
Free Cash Flow |
(28.14) | (32.00) | (41.74) | (32.47) | |
Working Capital |
314.24 | 281.80 | 247.68 | 211.33 | |
Capital Expenditures |
0.17 | 0.21 | (0.04) | (0.01) | |
Net Current Asset Value |
266.08 | 235.01 | 202.21 | 167.24 | |
EV/EBIT |
0.71 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.11) | (0.16) | 0.05 | 0.01 | |
Net Profit Margin |
(2,734.45%) | (3,014.93%) | (4,539.09%) | (4,762.03%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.90 | 2.43 | 1.42 | 1.00 | |
Average Payables |
2.23 | 3.27 | 2.56 | 2.80 | |
Average Assets |
483.74 | 451.85 | 411.00 | 373.83 | |
Average Common Equity |
381.58 | 367.41 | 344.06 | 306.46 |
Columns are period end dates